379
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia

, , , ORCID Icon, ORCID Icon & ORCID Icon
Pages 2754-2756 | Received 18 May 2022, Accepted 13 Jun 2022, Published online: 21 Jun 2022

References

  • Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood. 2020;135(11):804–813.
  • Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer. 2016;122(14):2178–2185.
  • Lenk L, Alsadeq A, Schewe DM. Involvement of the Central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data. Cancer Metastasis Rev. 2020;39(1):173–187.
  • Klinger M, Zugmaier G, Nägele V, et al. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 2020;80(1):91–101.
  • Alfayez M, Kantarjian HM, Short NJ, et al. Safety and efficacy of blinatumomab in patient with Central nervous system (CNS) disease: a single institution experience. Blood. 2018;132(Supplement 1):2702–2702.
  • Aldoss I, Otoukesh S, Zhang J, et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022;128(3):529–535.
  • Chen J, Ngo D, Rosenthal J. Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with Central nervous system disease. J Oncol Pharm Pract. 2019;25(8):2027–2030.
  • Foa R, Bassan R, Vitale A, GIMEMA Investigators, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–1623.
  • Badar T, Szabo A, Advani A, et al. Real-world outcomes of adult B-cell actue lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020;4(10):2308–2316.
  • Short NJ, Kantarjian H, Konopleva M, et al. Updated results of a phase II study of ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):2298–2298.
  • Aqel A, Fakhreddine O, Atoui A, et al. The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity. Curr Res Transl Med. 2021;69(2):103285.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.